Recent Updates
Recently added Catalysts
FLGT Negative Sentiment

Fulgent Reports Third Quarter 2026 Financial Results

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Fulgent Genetics reported its third quarter 2026 financial results, revealing a revenue of $90.4 million. The company experienced a GAAP loss of $13.2 million, translating to $(0.48) per share. Additionally, a non-GAAP loss of $2.4 million was reported, with an adjusted EBITDA loss of $7.5 million.

Market Sentiment Analysis

CONCERNS & RISKS

  • GAAP loss of $13.2 million reported.
  • Non-GAAP loss of $2.4 million noted.
  • Adjusted EBITDA loss of $7.5 million.

Full Press Release Details

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2026. Third Quarter 2026 Results: Revenue of $90.4 million GAAP loss of $13.2 million, or $(0.48) per share Non-GAAP loss of $2.4 million, or $(0.09) per share Adjusted EBITDA loss of $7.5 million No

Frequently Asked Questions

What was Fulgent's revenue for Q3 2026?

Fulgent reported a revenue of $90.4 million for Q3 2026.

What was the GAAP loss per share for Fulgent?

The GAAP loss was $(0.48) per share.

Did Fulgent report any non-GAAP losses?

Yes, Fulgent reported a non-GAAP loss of $2.4 million.

What was the adjusted EBITDA loss for Fulgent?

The adjusted EBITDA loss was $7.5 million.

ShareAdd on Google
Tags: FLGT Fulgent Genetics financial results Q3 2026 GAAP loss
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$551M liquidity · $8M/mo burn
~66 mo
Minimal dilution risk